Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from the same period last year but beat the ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other best stocks to buy and hold for 2025. Stocks have been performing well ...

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Follow us ...

Regeneron Pharmaceuticals, Inc. (REGN ... to the Centers for Medicare and Medicaid Services that were based on ASP, without accounting for price concessions – namely, credit card processing ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28 ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...